<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04019717</url>
  </required_header>
  <id_info>
    <org_study_id>AT-01B-002</org_study_id>
    <secondary_id>2019‐001431‐31</secondary_id>
    <nct_id>NCT04019717</nct_id>
  </id_info>
  <brief_title>Study of AT-527 in Combination With Daclatasvir in Subjects With Hepatitis C Virus (HCV) Infection</brief_title>
  <official_title>A Phase 2 Study Assessing the Safety and Efficacy of AT-527 in Combination With Daclatasvir in Subjects With Chronic HCV Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Atea Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Atea Pharmaceuticals, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will assess the safety and efficacy of AT-527 in combination with daclatasvir after
      8 or 12 weeks of treatment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 20, 2019</start_date>
  <completion_date type="Actual">March 23, 2020</completion_date>
  <primary_completion_date type="Actual">January 29, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Subjects will receive 8 or 12 weeks of treatment, based on treatment response.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of subjects achieving sustained virologic response (SVR)</measure>
    <time_frame>12 weeks after end of treatment</time_frame>
    <description>SVR defined as the HCV RNA &lt; lower limit of quantitation (LLOQ) at 12 weeks after end of treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of treatment-emergent adverse events</measure>
    <time_frame>Through 4 weeks after end of treatment</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Hepatitis C</condition>
  <condition>Hepatitis C, Chronic</condition>
  <condition>Chronic Hepatitis C</condition>
  <condition>Hepatitis C Virus Infection</condition>
  <condition>HCV Infection</condition>
  <arm_group>
    <arm_group_label>8 weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>12 weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AT-527</intervention_name>
    <description>Nucleotide prodrug inhibitor of HCV nonstructural protein 5B (NS5B) polymerase</description>
    <arm_group_label>12 weeks</arm_group_label>
    <arm_group_label>8 weeks</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daclatasvir</intervention_name>
    <description>Inhibitor of HCV nonstructural protein 5A (NS5A)</description>
    <arm_group_label>12 weeks</arm_group_label>
    <arm_group_label>8 weeks</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body mass index (BMI) of 18-35 kg/m2

          -  Must agree to use protocol-specified methods of contraception

          -  Negative pregnancy test

          -  HCV genotype 1

          -  Documented history compatible with chronic hepatitis C

          -  HCV RNA ≥ 10,000 IU/mL at Screening.

          -  Willing to comply with the study requirements and to provide written informed consent

        Exclusion Criteria:

          -  Pregnant or breastfeeding

          -  Infected with hepatitis B virus or HIV

          -  Abuse of alcohol or drugs

          -  Prior exposure to any HCV NS5A inhibitor

          -  Cirrhosis

          -  Use of other investigational drugs within 30 days of dosing

          -  Other clinically significant medical conditions or contraindications to daclatasvir
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiao-Jian Zhou, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Atea Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Antwerp</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Phoenix</city>
        <country>Mauritius</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Chisinau</city>
        <country>Moldova, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Mauritius</country>
    <country>Moldova, Republic of</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>July 11, 2019</study_first_submitted>
  <study_first_submitted_qc>July 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 15, 2019</study_first_posted>
  <last_update_submitted>May 1, 2020</last_update_submitted>
  <last_update_submitted_qc>May 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

